Financials
Financial year 2025
Gross margin
€ 870,849
▲ 232% vs 2024
Profit
Growing€ 363,834
▲ 127% vs 2024
Debts
Low€ 1.3 million
▲ 61% vs 2024
Abscint from Liège, company number BE0749828410, closed financial year 2025 with a result of € 363,834 after tax. For that financial year Abscint recorded a gross margin of € 870,849 and equity of € 5.6 million. Compared with financial year 2024, the result moved from € -1.3 million to € 363,834. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 6, 2026.
What happened at Abscint?
What happened at Abscint in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- NOSHAQ PARTNERS SCRL stepped down as director. NBB
- CBD Consulting SRL stepped down as director. NBB
- Didier Allaer stepped down as director. NBB
- Jacobus Boonen stepped down as director. NBB
- Koen DEWAELE stepped down as director. NBB
- Qbic Venture Partners II SA stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 363,834. Source: NBB ↗
- Koen DEWAELE became a director. NBB
In short
From € 237,892 loss in 2021 to € 363,834 profit in 2025.
Best year ever: 2025, with € 363,834 profit.
On average € 322,500 of value added per employee in 2025.
A new publication or filing at Abscint? We notify you, reason included.
Follow AbscintNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Directors
According to the 2025 annual accounts
Director · represented by Marleen LIMBOURG
Also active at: CAUTION MUTUELLE DES METIERS ET NEGOCES, Fonderies J. Marichal Ketin et Cie, DARDENNE +174 more
since 2022 · until 2028
Managing director · represented by Karine CLAUWAERT
Also active at: SILLAR CLINICAL
since 2022 · until 2028
since 2022 · until 2028
since 2022 · until 2028
Koen DEWAELE
Director
since 2023 · until 2028
Director · represented by Sofie BAETEN
Also active at: EYED PHARMA, Accelleran, Indigo Diabetes +9 more
since 2022 · until 2028
Establishments
Establishment units
Physical locations of this company
Boulevard de Patience et Beaujonc 3 box 23
4000 Liège
Researchdreef 12
1070 Anderlecht
Active since 1 March 2022
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 23 companies are registered at this address.
Hyloris Developments
€ 5.1 million revenue · 2025
ONCORADIOMICS same network
€ 2.4 million gross margin · 2025
DERMAX
€ 1.6 million revenue · 2025
Hyloris
€ 384,852 revenue · 2025
Hyloris Pharmaceuticals same network
€ 3.8 million revenue · 2025
+18 more
Details
- Company number
- 0749.828.410
- VAT number
- BE 0749.828.410
- Registered office
- Boulevard de Patience et Beaujonc 3 bus 23, 4000 Liège
- Names & denominations
- Abscint
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 6 July 2020
- Peppol
- Active · Active since 19 Jan 2026
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Activiteiten van medische beeldvorming en medische laboratoria
Activiteiten van medische laboratoria